Claims for Patent: 8,663,711

Summary for Patent: 8,663,711

Title:	Use of armillaridin for treating cancer
Abstract:	Novel Uses of an aromatic ester isolated from Armillaria mellea, particularly, armillaridin, are disclosed herein. The armillaridin is useful for manufacturing a medicament or a pharmaceutical composition for suppressing the growth of cancerous cells or for enhancing susceptibility of esophageal cancerous cells to a radiation treatment, in a subject.
Inventor(s):	Chen; Yu-Jen (Taipei, TW), Chen; Chien-Chih (Taipei, TW)
Assignee:	Mackay Memorial Hospital (New Taipei, TW)
Application Number:	13/342,642
Patent Claims:	1. A method of enhancing the susceptibility of esophageal cancer in a subject to a radiation therapy comprising administering to the subject an effective amount of armillaridin or a pharmaceutically acceptable salt thereof before irradiating the esophageal cancer with a radiation source at an energy of 1 to 10 mega volts. 2. The method of claim 1, wherein the radiation energy is 6 mega volts. 3. The method of claim 1, wherein the armillaridin or a pharmaceutically acceptable salt thereof is administered at a dose of 80 mg/Kg/day for at least 12 times. 4. The method of claim 1, further comprising administering to the subject an effective amount of a chemotherapy agent before, together with or after the administering of armillaridin. 5. The method of claim 4, wherein the chemotherapy agent is selected from the group consisting of an alkylating agent, an anthracycline, a plant alkaloid, a topoisomerase inhibitor, a cytotoxic antibiotic, and a tyrosine kinase inhibitor. 6. The method of claim 5, wherein the alkylating agent is cisplatin, carboplatin, oxaliplatin, cyclophosphamide, chlorambucil, or ifosfamide. 7. The method of claim 5, wherein the anthracycline is doxorubicin, daunorubicin, valrubicin, or idarubicin. 8. The method of claim 5, wherein the plant alkaloid is vincristine, vinblastine, taxol or docetaxel. 9. The method of claim 5, wherein the topoisomerase inhibitor is camptothecin (CPT), irinotecan (CPT-11) or topotecan (TPT). 10. The method of claim 5, wherein the cytotoxic antibiotic is antinomycin, bleomycin, mitomycin, or plicamycin. 11. The method of claim 5, wherein the tyrosine kinase inhibitor is imatinib, gefitinib, erlotinib, cetuximab, panitumumab, zalutumumab, nimotuzumab, or matuzumab.

Details for Patent 8,663,711

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2039-02-26
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2039-02-26
Amgen, Inc.	VECTIBIX	panitumumab	Injection	125147	09/27/2006		2039-02-26